Serum levels of autoantibodies of BALB/c recipients on day 15 after donor-cell injection
Donor cells, 50 × 106 . | Total IgG1, μg/mL . | Total IgG2a, μg/mL . | Anti-dsDNA IgG1, U/mL . | Anti-dsDNA IgG2a, U/mL . | Anti-dsDNA IgG2aa, U/mL . |
---|---|---|---|---|---|
DBA/2 whole SPL | 1157 ± 58 | 4033 ± 279 | 3162 ± 603 | 1459 ± 163 | <10 |
DBA/2 CD4--SPL | 484 ± 41 | 731 ± 60 | 407 ± 43 | 335 ± 41 | <10 |
DBA/2 CD8--SPL | 1953 ± 204 | 5051 ± 729 | 2630 ± 276 | 1073 ± 481 | <10 |
DBA/2 B220--SPL | 346 ± 43 | 455 ± 42 | 225 ± 46 | 140 ± 16 | <10 |
No injection | 97 ± 5 | 43 ± 4.2 | <10 | <10 | <10 |
NZB SPL* | NA | NA | NA | 366 ± 79 | 293 ± 32 |
Donor cells, 50 × 106 . | Total IgG1, μg/mL . | Total IgG2a, μg/mL . | Anti-dsDNA IgG1, U/mL . | Anti-dsDNA IgG2a, U/mL . | Anti-dsDNA IgG2aa, U/mL . |
---|---|---|---|---|---|
DBA/2 whole SPL | 1157 ± 58 | 4033 ± 279 | 3162 ± 603 | 1459 ± 163 | <10 |
DBA/2 CD4--SPL | 484 ± 41 | 731 ± 60 | 407 ± 43 | 335 ± 41 | <10 |
DBA/2 CD8--SPL | 1953 ± 204 | 5051 ± 729 | 2630 ± 276 | 1073 ± 481 | <10 |
DBA/2 B220--SPL | 346 ± 43 | 455 ± 42 | 225 ± 46 | 140 ± 16 | <10 |
No injection | 97 ± 5 | 43 ± 4.2 | <10 | <10 | <10 |
NZB SPL* | NA | NA | NA | 366 ± 79 | 293 ± 32 |
Data are presented as means ± SE; n = 10.
CD4--SPL indicates CD4+ T cell–depleted spleen cells; CD8--SPL, CD8+ T cell–depleted spleen cells; B220--SPL, B220+ B cell–depleted spleen cells; and NA, not applicable.
IgG2a antibodies secreted by B cells from NZB mice are allotype a, and serum of BALB/c recipients given donor NZB spleen cells was used as positive control for anti-dsDNA IgG2aa